JeffreyE.GershenwaldMDFACS, FAAAS, FRACS(Hon)
General Surgery • Houston, TXSurgical Oncology (Other than Breast)
Dr. John M. Skibber Professor, Department of Surgical Oncology The University of Texas MD Anderson Cancer Center
Dr. Gershenwald is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161- Is this information wrong?
Summary
- Dr. Jeffrey Gershenwald is a general surgeon in Houston, TX and is affiliated with University of Texas M.D. Anderson Cancer Center. He received his medical degree from Weill Cornell Medicine and has been in practice 27 years. He specializes in surgical oncology (other than breast) and is experienced in surgical oncology (non-breast).
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Complex General Surgical Oncology, 1995 - 1998
New York Presbyterian Hospital (Cornell Campus)Residency, Surgery, 1990 - 1995
Weill Cornell MedicineClass of 1990
Certifications & Licensure
WA State Medical License 2023 - 2025
TX State Medical License 1995 - 2025
AZ State Medical License 2023 - 2025
MS State Medical License 2023 - 2024
TN State Medical License 2023 - 2024
NY State Medical License 1992 - 2024
AL State Medical License 2023 - 2024- American Board of Surgery Surgery
- Join now to see all
Awards, Honors, & Recognition
- Honorary Fellow, Royal Australasian College of Surgeons (RACS) Royal Australasian College of Surgeons, 2021
- AACR Team Science Award American Association for Cancer Research, 2020
- Fellow, American Association for the Advancement of Science (AAAS) American Association for the Advancement of Science, 2018
- Join now to see all
Clinical Trials
- Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma Start of enrollment: 2019 Dec 17
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.Dedeilia, A., Alexander H R Varey, Isabel Li, Mary-Ann El Sharouni, Julie Simon, Aikaterini Dedeilia, Sydney Ch'ng, Robyn P M Saw, Andrew J Spillane, Kerwin F Shannon,...> ;Journal of Clinical Oncology. 2024 Apr 1
- Health Economic Consequences Associated With COVID-19-Related Delay in Melanoma Diagnosis in Europe.Maul, L., Jamiolkowski, D., Lapides, R., Mueller, A., Hauschild, A., Garbe, C., Lorigan, P., Gershenwald, J., Ascierto, P., Long, G., Wang-Evers, M., Scolyer, R., Sara...> ;JAMA Network Open. 2024 Feb 5
- 1 citationsPrimary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes.Samuel Cass, Brandon Cope, Andrew J Bishop, Yi-Ju Chiang, B Ashleigh Guadagnolo, Ahsan Farooqi, William Morrison, Russell G Witt, Riyad N H Seervai, Adam S Garden, Cli...> ;Radiotherapy and Oncology. 2023 Nov 1
- Join now to see all
Journal Articles
- Publisher Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaScott Woodman, Alexander J Lazar, Michael A Davies, Neil Gross, Sapna P Patel, Isabella C Glitza, Ehab Hanna, Stephen Y Lai, Richard Ehlers, Amy Hessel, Padmanee Sharm..., Nature
- Author Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaJanice N Cormier, Ehab Hanna, Padmanee Sharma, Jennifer A Wargo, Isabella C Glitza, Sapna P Patel, Adi Diab, Jeffrey E Lee, Richard Royal, Randal Weber, Patrick Hwu, J..., Nature
- Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaRichard Royal, Alexander J Lazar, Adi Diab, Sapna P Patel, Jeffrey E Lee, Padmanee Sharma, Patrick Hwu, Randal Weber, Jeffrey Gershenwald, Carol Lewis, Richard Ehlers,..., Nature
- Join now to see all
Lectures
- Malignant Melanoma Prevention: Lifestyle Changes and Legislation2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Other
- Correction to: Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and BeyondJeffrey Gershenwald, MD, Annals of Surgical Oncology
https://www.doximity.com/articles/ce96a6ac-03c0-43cd-9b57-9a526c8d8262
UpToDate, Wolters Kluwer Health - 2013-03-21
Press Mentions
Melanoma Survivor: Protect Your SkinMarch 19th, 2019- Stage IV Salivary Gland Cancer Survivor: How Proton Therapy Saved My CareerJanuary 9th, 2019
- Guidelines of Care for the Management of Primary Cutaneous MelanomaJanuary 1st, 2019
- Join now to see all
Grant Support
- Informatics, Tissue Resource, And Pathology CoreNational Cancer Institute2010–2011
- Core--Informatics, Tissue Resource, And PathologyNational Cancer Institute2007–2008
- Molecular Epidemiology Of Genetic Markers In MelanomaNational Cancer Institute2004–2008
- Core--Nformatics, Tissue Resource, And PathologyNational Cancer Institute2004–2006
Professional Memberships
- Member
- Member
Hospital Affiliations
University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
